drugset
drugset / Trial / NCT02873156

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2027 in Healthy Subjects

NCT02873156 ↗

Phase 1 Completed 74 enrolled Eisai Inc.
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of multiple ascending oral doses of E2027 in healthy participants.

Timeline

Start
2016-08-10
Primary completion
2017-11-29
Completion
2017-11-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Irsenontrine Small molecule 5 mg Oral
Subject Irsenontrine Small molecule 10 mg Oral
Subject Irsenontrine Small molecule 25 mg Oral
Subject Irsenontrine Small molecule 50 mg Oral
Subject Irsenontrine Small molecule 100 mg Oral
Subject Irsenontrine Small molecule 200 mg Oral
Subject Irsenontrine Small molecule 400 mg Oral

Indications

No indication recorded.